VRAX
What one share of Virax Biolabs Group holds
In Vitro and In Vivo Diagnostic Substances
Virax Biolabs Group Limited is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of its own, we conduct substantially all of our operations through subsidiaries in the United Kingdom, the United States and China.
Virax Biolabs Group’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.03 |
|---|---|
| Profit | −$12.64 |
| Capex (buildings and equipment) | $0.64 |
| Free cash flow | −$12.27 |
| Cash and investments | $11.12 |
| Book value | $13.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.00 | −$44.67 | — | −$21.15 | — | −$24.42 |
| 2023 | $0.20 | −$128.35 | — | −$98.30 | — | $146.75 |
| 2024 | $1.95 | −$83.90 | $11.87 | −$91.57 | — | $52.13 |
| 2025 | $0.04 | −$40.62 | $4.05 | −$34.63 | — | $32.80 |
| 2026 | $0.03 | −$12.64 | $0.64 | −$12.27 | — | $13.08 |